223 related articles for article (PubMed ID: 17015049)
1. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S; Buclin T; Décosterd LA; Telenti A; Furrer H; Lee BL; Biollaz J; Eap CB;
Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
3. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
4. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
[TBL] [Abstract][Full Text] [Related]
9. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
10. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.
Dailly E; Allavena C; Raffi F; Jolliet P
Br J Clin Pharmacol; 2005 Jul; 60(1):32-4. PubMed ID: 15963091
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
[TBL] [Abstract][Full Text] [Related]
15. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2002 Apr; 24(2):302-9. PubMed ID: 11897976
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
18. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
[TBL] [Abstract][Full Text] [Related]
19. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
